CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound represented by formula 1:



(1)

wherein

$\mathbf{R^1}$ is selected from the group consisting of H, halogen, $(C_{1\text{-}4})$alkyl, $O(C_{1\text{-}4})$alkyl, and haloalkyl;

$\mathbf{R^2}$ is H or Me;

$\mathbf{R^3}$ is H or $(C_{1\text{-}4})$alkyl;

$\mathbf{R^4}$ is H or $(C_{1\text{-}4})$alkyl;

$\mathbf{R^5}$ is $(C_{1\text{-}4})$alkyl, $(C_{1\text{-}4})$alkyl$(C_{3\text{-}7})$cycloalkyl, or $(C_{3\text{-}7})$cycloalkyl; and

W is selected from:



wherein,

a) one of **Y** is SO_2 and the other **Y** is $\mathbf{NR^6}$, provided that both are not the same, wherein $\mathbf{R^6}$ is selected from the group consisting of: H, $C(O)O(C_{1\text{-}4})$alkyl, $(C_{1\text{-}4})$ alkyl or $(C_{1\text{-}4})$ alkyl substituted with either a pyridinyl-N-oxide or $C(O)OR^8$ wherein $\mathbf{R^8}$ is H or $(C_{1\text{-}4})$ alkyl; and each $\mathbf{R^9}$ is independently H or $(C_{1\text{-}4})$ alkyl; and

b) **E** is $CR^{10}R^{10}$ wherein each R^{10} is independently H or (C_{1-4}) alkyl, J is CH_2 and the dotted line represents a single bond; or

c) **E** and **J** are both CR^{11} wherein R^{11} is H or (C_{1-4}) alkyl and the dotted line represents a double bond; or

W is selected from:



wherein,

m is 1 or 2,

R^{12} is H or $C_{(1-4)}$ alkyl,

R^{13} is H or (C_{1-4}) alkyl, and

Z is **O** or **Z** is NR^{14} wherein R^{14} is H or (C_{1-4}) alkyl; or

W is selected from a group of aromatic radicals consisting of:





,


and


wherein R^{15} is (C_{1-4}) alkyl or CF_3, and n is the integer 0, 1 or 2, or a pharmaceutically acceptable salt~~,~~ or ester ~~or a prodrug~~ thereof.

Claim 2 (original): The compound according to claim 1, wherein R^1 is selected from the group consisting of: H, Cl, F, (C_{1-4}) alkyl and CF_3; R^2, R^3 and R^4 is each independently H or Me; R^5 is ethyl or cyclopropyl;

W is:



wherein **Y** is SO_2 and the other **Y** is NR^6, provided that both are not the same, R^6 is H, C(O)OMe, C(O)OEt, (4-pyridinyl-N-oxide)methyl, $CH_2C(O)OH$, $CH_2C(O)OMe$, $CH_2C(O)OEt$ or $CH_2C(O)OCMe_3$, and each R^9 is independently H or Me; or

wherein **E** is $CR^{10}R^{10}$ wherein each of R^{10} is independently H or Me, **J** is CH_2 and the dotted line represents a single bond; or both **E** and **J** are CR^{11} wherein R^{11} is H or Me and the dotted line represents a double bond; one of **Y** is SO_2 and the other **Y** is NR^6 wherein R^6 is hydrogen or methyl; or



,


,


,


.

,



wherein R^{15} is Me or Et, and n is 0 or 1.

Claim 3 (original): The compound according to claim 2, wherein R^{15} is Me.

Claim 4 (original): The compound according to claim 3, wherein R^1 is H, Cl, F and Me; R^2 is H or Me;

W is:



wherein **Y** is SO_2 and the other **Y** is NR^6, provided that both are not the same, R^6 is H, C(O)OEt, (4-pyridinyl-N-oxide)methyl, $CH_2C(O)OH$, $CH_2C(O)OMe$, $CH_2C(O)OEt$ or $CH_2C(O)OCMe_3$, and each R^9 is independently H or Me.

Claim 5 (original): The compound according to claim 4, wherein **R**^{3} is Me, **R**^{6} is H, C(O)OEt or (4-pyridinyl-N-oxide)methyl, and **W** is:



Claim 6 (original): The compound according to claim 4, wherein **W** is:



wherein one **Y** is SO_2 and the other **Y** is N**R**^{6}, provided that both are not the same, **R**^{6} is H, C(O)OEt, $CH_2C(O)OH$, $CH_2C(O)OCMe_3$, (4-pyridinyl-N-oxide)methyl; and each **R**^{9} is independently H or Me.

Claim 7 (original): The compound according to claim 6, wherein **R**^{6} is H and each **R**^{9} is Me.

Claim 8 (cancelled)

Claim 9 (cancelled)

Claim 10 (cancelled)

Claim 11 (currently amended): A pharmaceutical composition for the treatment ~~or prevention~~ of HIV infection, comprising a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt~~,~~ or ester ~~or prodrug~~ thereof, in combination with a pharmaceutically acceptable carrier.

Claim 12 (currently amended): A method for the treatment ~~or prevention~~ of HIV infection, comprising administering to a patient an HIV inhibiting amount of a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt~~,~~ or ester ~~or prodrug~~ thereof.

Claim 13 (currently amended): A method for the treatment ~~or prevention~~ of HIV infection, comprising administering to a patient an HIV inhibiting amount of a pharmaceutical composition according to claim 11.

Claim 14 (original): A process for producing a compound of formula 1 according to claim 1, comprising the step:

- coupling a compound of formula 2:



(2)

wherein $\mathbf{R^1}$, $\mathbf{R^2}$, $\mathbf{R^3}$, $\mathbf{R^4}$, and $\mathbf{R^5}$ are as defined in claim 1, with a phenolic derivative selected from:





,



,



,



,



,



,



,



,



, and



,

wherein PG^1 is a nitrogen protecting group and PG^2 is a carboxy protecting group, said protecting groups being removable under mildly acidic, mildly alkaline or reductive conditions, and **R^6, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}**, m, n, and **Z** are as defined in claim 1.

Claim 15 (original): The process according to claim 14, wherein said nitrogen protecting group is selected from: alkyl esters; aralkyl esters; and esters that can be cleaved by mild base treatment or mild reductive means.

Claim 16 (original): The process according to claim 14, wherein said carboxy protecting group is selected from: Boc (*tert*-butyloxycarbonyl) and alkyl carbamates.

Claim 17 (original): An intermediate compound of formula 2:



(2)

wherein **R**^{1}, **R**^{2}, **R**^{3}, **R**^{4}, and **R**^{5} are as defined in claim 1.